Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial (2021)

First Author: Pollock K

Attributed to: saRNA SARS-CoV-2 vaccine funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2139/ssrn.3859294

Publication URI: http://dx.doi.org/10.2139/ssrn.3859294

Type: Journal Article/Review

Parent Publication: SSRN Electronic Journal